Company Overview

argenx SE is a global commercial-stage biopharmaceutical company dedicated to developing innovative antibody-based therapies for severe autoimmune diseases. Founded in 2008 and headquartered in Amsterdam, the Netherlands, argenx has established itself as a leader in the immunology space. The company operates globally, with significant presence in the United States, Japan, China, and the Netherlands, focusing on improving the lives of patients suffering from debilitating autoimmune conditions through cutting-edge science and patient-centric collaboration.

With a market capitalization of $33.91 billion, argenx trades on both Euronext and Nasdaq under the ticker symbol ARGX.

Core Products and Commercial Success

argenx's commercial success is driven by its innovative antibody-based therapeutics targeting autoimmune diseases.

VYVGART Portfolio

The company's flagship product line includes VYVGART (efgartigimod alfa) and VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc). These therapies are approved for the treatment of generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).

* Vyvgart (efgartigimod alfa): Received FDA approval in December 2021 for gMG.

* Vyvgart Hytrulo: A subcutaneous formulation approved in 2022, offering a more convenient administration route. In 2024, it was approved by the FDA for CIDP, a rare immune-mediated neuromuscular disorder.

Strong Financial Performance

The company has demonstrated impressive commercial execution with robust revenue growth from its product sales:

* Q2 2025: Reported $949 million in global product net sales.

* Q1 2025: Recorded $790 million in global product net sales.

* Q2 2025 Growth: Revenues surged by 97% year-over-year, with VYVGART reaching over 15,000 patients globally across its approved indications.

Extensive Pipeline and Development Programs

argenx is actively advancing a broad pipeline of novel therapies, underpinned by its "Vision 2030" strategy, which aims to treat 50,000 patients globally, secure 10 labeled indications, and advance five pipeline candidates into Phase 3 development by 2030.

Key Pipeline Candidates

* Efgartigimod Expansion: Efgartigimod is under investigation for 15 severe autoimmune diseases, exploring the potential of FcRn biology across neurology, rheumatology, and new therapeutic areas. Registrational studies are ongoing for subsets of myositis, thyroid eye disease (TED), and Sjögren's disease.

* ARGX-119: This candidate is being evaluated for congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). Following positive proof-of-concept data, ARGX-119 is set to advance to a registrational study in CMS.

* Immunology Innovation Program (IIP): The IIP has led to the nomination of four new pipeline candidates: ARGX-213 (targeting FcRn), ARGX-121 (a first-in-class molecule targeting IgA), ARGX-109 (targeting IL-6), and a fourth undisclosed candidate.

Clinical Development Scale

The company is managing 10 Phase 2 and 10 Phase 3 studies across its key programs like efgartigimod, empasiprubart, and ARGX-119, creating significant opportunities for expansion into new therapeutic areas and broader patient populations.

Strategic Collaborations

argenx collaborates with a wide network of partners to fuel its research and development. Key collaborations include those with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd.

Recent Developments and Market Position

argenx continues to solidify its market leadership through product innovation and regulatory achievements. The company received approval for its pre-filled syringe for self-injection in the United States, which carries an optimal label supporting earlier patient access. The recent launch of the VYVGART SC prefilled syringe has been met with strong market reception, driving demand and enhancing the company's delivery options. The VYVGART SC launch in CIDP is progressing well, with over 2,500 patients currently on treatment globally.

argenx presents a compelling growth narrative in the biotechnology sector, marked by a successful commercial product portfolio and an ambitious pipeline targeting diverse autoimmune conditions. Its strategic focus on FcRn biology and novel therapeutic approaches positions the company for sustained expansion within the global immunology market.